Mast cell activation syndrome (MCAS) is not an autoimmune disease. Although both conditions involve the immune system behaving abnormally, the underlying problem in MCAS is fundamentally different from what happens in autoimmune disorders. In autoimmune diseases, the immune system produces antibodies that mistakenly attack the body’s own tissues. In MCAS, mast cells release chemicals like histamine when there’s no real threat, causing widespread symptoms across multiple organ systems.
Why MCAS Is Not Autoimmune
The distinction comes down to which part of the immune system malfunctions and how. Autoimmune diseases, such as lupus or rheumatoid arthritis, are driven by the adaptive immune system. Your body creates antibodies that target your own cells as if they were foreign invaders, gradually damaging specific tissues or organs.
MCAS involves the innate immune system, specifically mast cells. These cells normally sit in your tissues waiting to detect harmful invaders like parasites or viruses. When they sense a threat, they release histamine and other chemical mediators to trigger inflammation and flush out the intruder. In MCAS, this release happens without a clear trigger. The mast cells aren’t attacking your tissues the way autoantibodies do. Instead, they’re dumping chemicals into surrounding tissue inappropriately, and it’s those chemicals that cause symptoms.
Mast cells can be activated through a surprisingly wide range of pathways. Beyond the classic allergy pathway involving IgE antibodies, they respond to complement proteins, signals from nearby nerve endings, stress hormones, ATP released from damaged cells, and various immune signaling molecules. This is one reason MCAS symptoms can seem to flare in response to almost anything: physical stress, temperature changes, strong emotions, or foods that aren’t true allergens.
The Three Types of MCAS
Doctors classify MCAS into three categories based on what’s driving the mast cell dysfunction. Primary MCAS involves a genetic change that causes a group of mast cells to grow abnormally. This form is linked to conditions like mastocytosis or monoclonal mast cell activation syndrome, where the mast cells themselves are inherently abnormal.
Secondary MCAS occurs when another illness or condition triggers the mast cell activation. A common example is an IgE-dependent allergy, but other underlying diseases can also provoke it. When secondary MCAS is identified, treating the underlying condition can help calm the mast cell activity as well.
Idiopathic MCAS is diagnosed when all the diagnostic criteria are met but no underlying disease or abnormal cell growth can be found to explain it. This is likely the most frustrating category for patients, because the mast cells appear normal under a microscope and there’s no identifiable root cause.
How MCAS Differs From Mastocytosis
People often confuse MCAS with systemic mastocytosis, but the two conditions have distinct symptom profiles. Mastocytosis tends to cause more systemic, deep-tissue problems: fainting, memory difficulties, weight loss, depression, anemia, bone thinning, and enlarged lymph nodes or organs. MCAS, on the other hand, leans more toward surface-level and reactive symptoms: hives, facial flushing, swelling, low blood pressure, bloating, belching, runny nose, sneezing, and wheezing.
In mastocytosis, there is a measurable increase in the number of mast cells in the body, often linked to a specific genetic mutation. In MCAS, the number of mast cells is typically normal. The cells are just behaving badly.
How MCAS Is Diagnosed
Diagnosing MCAS requires meeting three criteria simultaneously: recurring episodes of mast cell activation symptoms affecting at least two organ systems, a measurable rise in mast cell mediators during a flare, and improvement with medications that block or stabilize mast cells.
The key lab marker is tryptase, a protein released during mast cell degranulation. To count as evidence of MCAS, your tryptase level during a symptomatic episode needs to exceed 20% of your personal baseline plus 2 ng/mL. This formula matters because tryptase levels vary widely between individuals. A level that’s elevated for you might be perfectly normal for someone else. Timing is critical: the blood draw needs to happen during or shortly after a flare, which makes it logistically difficult to capture.
The Overlap With Autoimmune Conditions
Part of the reason people wonder whether MCAS is autoimmune is that it frequently appears alongside conditions that have autoimmune features. MCAS is often discussed in the same breath as postural orthostatic tachycardia syndrome (POTS) and Ehlers-Danlos syndrome (EDS), a triad that shows up repeatedly in patient communities. However, the formal evidence supporting a confirmed biological link between these conditions is thin. A 2025 systematic review in the Annals of Allergy, Asthma & Immunology found no studies that met strict diagnostic criteria for simultaneously confirming mast cell activation disorders alongside POTS or EDS. One study came close, showing an association, but the overlap remains more of a clinical observation than a proven relationship.
This doesn’t mean the overlap isn’t real for individual patients. It means the research hasn’t yet caught up with what many people experience. Mast cells interact with so many body systems, including nerves, blood vessels, and connective tissue, that plausible biological explanations exist for why these conditions might cluster together.
How MCAS Is Managed
Because MCAS isn’t autoimmune, it isn’t treated with the immune-suppressing drugs used for autoimmune diseases. Instead, treatment focuses on blocking the chemicals that mast cells release and stabilizing the cells themselves. Most people with MCAS take a layered combination of medications.
The foundation is two types of antihistamines used together. H1 antihistamines (like cetirizine or fexofenadine) target itching, flushing, headaches, and brain fog. H2 antihistamines (like famotidine) address gastrointestinal symptoms and provide additional mast cell stability. Both types are considered necessary because they stabilize different receptors on the mast cell surface.
Beyond antihistamines, mast cell stabilizers like oral cromolyn sodium or ketotifen can help with gut symptoms and cognitive fog. Leukotriene inhibitors target respiratory symptoms like wheezing and also contribute to overall mast cell stability. For patients with elevated prostaglandin levels, aspirin therapy under medical supervision can reduce flushing, brain fog, and bone pain. Some people also use bioflavonoid supplements like quercetin and luteolin, which have mild mast cell stabilizing properties.
All patients with a mast cell disease are advised to carry two doses of injectable epinephrine at all times, even if they have never experienced anaphylaxis. Mast cell degranulation can escalate unpredictably, and severe reactions, while not routine, are a known risk. The medications used for MCAS manage symptoms and reduce flare severity, but they do not cure or modify the underlying mast cell dysfunction itself.